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ABSTRACT  
 
Pentoxifylline (PTX) is a methylxanthine derivative used in a wide range of dermatoses. 
As well as its hemorrheologic activity, PTX has anti-inflammatory properties. 
Buflomedil chlorhydrate (BC) is another hemorrheological drug with peripheral 
vasodilatory action, whose clinical uses are similar to those of PTX. Both drugs increase 
intracellular levels of cAMP, either secondary to phosphodiesterase inhibition (PTX) or 
adenyl-cyclase stimulation (BC). Long-term cultures of normal human keratinocytes 
were prepared in a free-serum medium, and stimulated with 1 mg/ml of phorbol 12-
myristate 13-acetate (TPA) and PTX or BC (100-1000 µg/ml). Levels of TNF-α, IL-1α, 
IL-1β, IL-8 and TGF-β1 using ELISA and Northern blot or RT-PCR techniques were 
measured. TPA-induced TNF-α and IL-8 release from keratinocytes. TPA did not 
induce IL-lα or IL-1β release of keratinocytes. TPA increased RNA expression of the 
TNF-α, IL-lα, IL-1β, IL-8 and TGF-β1. BC diminished TPA-induced TNF-α and IL-8 
release from keratinocytes; in the case of IL-8 it is possible that this inhibition occur to 
transcriptional level. Moreover PTX was unable to inhibit TNF-α and IL-8 synthesis 
and expression. PTX and BC reduced TPA-induced IL-lα and β expression. It is 
possible that BC action is specifically exerted on keratinocytes, because we did not find 
similar results with TNF-α and IL-8 synthesis in mononuclear peripheral blood cells. 
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INTRODUCTION 
 
The keratinocyte, the main constituent cell in the epidermis, may respond to numerous 
external stimuli by producing certain cytokines which are responsible for the initial 
phase of various inflammatory skin diseases; it may therefore be regarded as an immune 
cell capable of triggering an inflammatory response (1-4). It is known that keratinocytes 
are capable of secreting the following cytokines, among others: TNF-α, IL-lα, IL-lβ, IL-
3, IL-5, IL-6, IL-7 (5), IL-8, IL-10 (6), IL-11, IL-12, GM-CSF, G-CSF, M-CSF (7, 8), 
TGF-α, TGF-β and PDGE Complex interaction between these cytokines occurs in the 
epidermis; each one may have diverse inflammatory effects, and at very low 
concentrations they may facilitate and improve the transendothelial migration of other 
inflammatory cells (9). Pentoxifylline (PTX) is a methylxanthine derivative that has 
been used therapeutically for quite a long time in a huge number of patients suffering 
from vascular disorders (10). Its hemorrheological, antiaggregant and anti-inflammatory 
properties, and its ability to protect the vascular endothelium has led to its use in a wide 
range of dermatoses (11, 12). Additionally to its hemorrheologic activity, PTX has 
recently been found to suppress the production of TNF-α by murine and human 
leucocytes (13). The majority of studies involving PTX reported in the literature were 
performed on LPS-stimulated monocytes, and there are no specific studies using 
keratinocyte cultures. We are unaware of any studies of the action of PTX on cell lines 
stimulated by using phorbol derivates (TPA). 
Buflomedil chlorhydrate (BC) is another hemorrheological drug with peripheral 
vasodilatory action, whose clinical applications are similar to those of PTX. Of 
particular interest among its effects are the increase in erythrocyte deformability, the 
encouragement of platelet antiaggregation, and the increase in tissue oxygenation and 
collateral circulation (14). There is wide clinical experience in the use of BC in the 
treatment of peripheral vascular disease, and its pharmacokinetics and tolerante are well 
known (15), even though acute BC intoxication has been published (16). Some studies 
have also shown the efficacy of this drug in diabetic microangiopathy, Raynaud's 
disease (17) and in the treatment of trophic skin lesions associated with vascular 
insufficiency. In vitro studies on human neutrophils showed that BC reduces 
aggregation, formation of pseudopods and, therefore, adhesion and degranulation of 
lisosomial enzymes (18). BC can play a role in adhesive molecule expression on the 
leukocyte and endothelial cells (19). Increase in cAMP, secondary to the stimulation of 
adenyl cyclase by BC, has been reported. In the same way as PTX, BC may exert a 
modulatory effect on cytokine synthesis, although there are no in vitro or in vivo studies 
about this action. 
Phorbol esters are well-known to induce the transcription of several genes, among them 
those coding for the inflammatory cytokines TNF-α, IL-lα, IL-1β, IL-6 and IL-8. In this 
study these data are verified in a culture of keratinocytes, and then the possible 
modulatory effects of PTX and BC with respect to the expression and synthesis of these 
cytokines are tested. 
 
 
MATERIALS AND METHODS  
 
Cell culture 
Long-term cultures of normal human KC were prepared from human female breast skin 
as described previously (20) with some modificatíons. Briefly, skin samples were 
washed in phosphatebuffered salive (PBS) and connective tissue was trimmed. The skin 
samples were then treated by 1% dispase (Boehringer Mannheim, Madrid, Spain) in 
PBS with gentamycin (20 mg/m1) at 37°C overnight. Epidermal sheets were peeled 
from the dermis and stirred in 0.05% trypsin and 0.53 mM ethylenediamine tetra-acetic 
acid (EDTA) solution (trypsin-EDTA solution) for 10 min at 37°C. The trypsin-EDTA 
solution was inactivated with Eagle's minimum essential medium (MEM) with 10% 
fetal bovine serum (FBS) (Gibco BRL, Zaragoza, Spain), and cells centrifugated at 
1000 x g for 10 min. Cell pellets were resuspended in 10 ml of complete keratinocyte 
serum free medium (KSFM) containing bovine pituitary extract (BPE) and epidermal 
growth factor (EGF; Gibco BRL, Zaragoza, Spain) and cultured at 37°C in a humidified 
atmosphere of 5% CO2, in tissue culture 75 cm2 (Nunclon, Denmark). Cultures were fed 
every third day and after confluency they were subcultured by trypsin-EDTA solution 
followed by addiction of Eagle's MEM with 10% FBS and centrifugation, and replated 
at a split ratio of 1:3. Testing of third-passage cells was carried out at 70-80% 
confluency. Cell viability was determined bly trypan blue exclusion and by flow 
cytometry using propidium iodide. Similar levels of viability were detected before and 
after incubation with the different drugs and concentrations used (>85%). No significant 
changes in keratinocytes viability was found for any of the PTX or BC concentrations 
evaluated. We changed the complete K-SFM to basal medium without BPE and EGF 72 
h before testing to avoid a medium-changing effect on cytokine production (21, 22). 
Data were generated using KC from three different donors. 
 
 
Phorbol 12-myristate 13-acetate, buflomedil and pentoxifylline preparation 
Phorbol 12-myristate 13-acetate (TPA, Sigma, Madrid, Spain) was dissolved in DMSO 
(1000 mg/ml). Buflomedil and Pentoxifylline (Sigma, Madrid, Spain) were disolved in 
salive and utilized at concentrations of 100 and 1000 µg/ml. 
 
TNF-α, IL-lα, IL-1β, IL-6 and IL-8 Enzvinelinked innnunosorbeizt assay (ELISA) 
Commercially available ELISA kits (R&D Systems, Minneapolis, MN) were used to 
measure human TNF-α, IL-1α, IL-1β, IL-6 and IL-8 proteins levels in cell-free 
supernatants. These kits are based on the use of a mouse anti-cytokine monoclonal 
antibody and a polyclonal antibody agaínst cytokine, conjugated to horseradish 
peroxidase. These kits are sensitive from 0.3-5 pg/ml, and do not crossreact with any 
other known cytokines at concentrations between 50-100 ng/ml. Each supernatant was 
analyzed in duplicate. 
 
Northern blot analysis 
Northern blot analysis of cytokine RNA expression was performed (23). Cultured KC 
were gently detached, resuspended in guanidinium isothiocyanate (Sigma, Madrid, 
Spain), and extracted with an equal volume of acetate/EDTA-equilibrated phenol (60°C 
for 25 min with frequent vortexing). The aqueous phase was recovered after 
centrifugation and extracted once with an equal volume of phenol/chloroform and twice 
with chloroform. The resulting RNA was precipitated overnight at —20°C with 2.5 
volumes of ethanol. 
After extraction, the amount of total RNA was measured by a spectrophotometer 
Lambda Bio UVNIS (Perkin Elmer, Madrid, Spain). The purified RNA was quantified 
by optical density at 260 nm. Five mg of RNA from each sample was then 
electrophoresed on a 1% agarose gel containing 20 mM sodium borate, pH 8.3, 0.5 mM 
EDTA, and 3% formaldehyde. Ribosomal RNA 18S and 28S were determined by UV 
visualization after ethidium bromide staining and the RNA was transferred to 
nitrocellulose paper (Schleicher and Schuell, Dasel, Germany) in 10x (SSC) (1.5 M 
sodium chloride and 150 mM sodium citrate) using capillary blotting overnight. The 
blots were baked at 80°C under vacuum for 2 h, and prehybridized at 55°C in Rapid-
hyb buffer (RPN 1635, Amersham) for at least 45 min. TNF-α, IL-lα, IL-1β and TGF- 
β1  were obtained of the pAW737, phIL1 - AcDNA, YEpsecl and phTGFβ-2 plasmids 
(American Type Culture Collection) respectively. For control hybridization a cDNA 
probe encoding for the house-keeping protein β-actin was used (HHCI89 plasmid, 
American Type Culture Collection). cDNA fragments were radiolabeled by random 
priming with a 32P-dCTP (>6000 Ci/mmol) (Stratagene, La Jolla, California). 
Hybridization was performed over 2 h at 55°C. The blots were then washed twice in 2X 
SSC and 0.1% sodium dodecylsulfate (SDS) at room temperature followed by a 2x 
high-stringency wash in 0.1x SSC at 65°C. Autoradiography was carried out at —80°C 
by using Kodak X-omat film (Eastman Kodak, Rochester, NY) with an intensifying 
screen. The developed autoradiographs were scanned by a BioRad Model 620 Video 
Densitometer (BioRad, Bilbao, Spain). 
 
Polymerase chain reaction analysis 
Total RNA from keratinocytes was extracted by the guanidinium thiocyanate/phenol-
chloroform procedure (23). The total amount of RNA was quantitated by 
spectrophotometry. Using equal amounts of RNA, cDNA was synthesized by reverse 
transcription using GeneAmp RNA PCR kit (Perkin-Elmer) following the 
manufacturer's instructions. Primers for amplifying IL-8 (US: GAG AAG TTT TTG 
AAG AGG CTG AGA A, and DS: CTG TGA GGT AAG ATG GTG GCT AAT A) 
were designed using Oligo 4.0 software and synthesized and high performance liquid 
chromatography-purified by Bio-Synthesis (Texas, USA). β-Actin control primers were 
obtained from Clontech (California, USA). A hot-start PCR protocol with cDNA 
templates after reverse transcriptase was used. The PCR master mix contained 1.25 U 
Taq polymerase (Perkin-Elmer), 0.1 mM dNTPs (Perkin-Elmer), 10x PCR buffer (100 
mM TrisHC1, pH 8.3; 500 mM KCI; 15 mM MgC12; 0.01% wt/vol gelatin; autoclaved, 
Perkin-Elmer), 20-50 pmol each of 5'-3' primers and deionized water in a total volume 
of 50 ml. The reaction was carried out in a thermocycler 2400 (Perkin-Elmer) and 
consisted of 30 cycles of denaturing at 94°C for 1 min, annealing at 53°C for 1 min and 
extension at 72°C for 90 s. A second round of PCR was performed using internal 
primers according to confirm the PCR product. The PCR cycle and primer 
concentration dependency of signal strength were preliminary optimized. For each 
experiment, internal controls lacking template were performed and verified to be 
negative. PCR using total RNA without reverse transcriptase reaction as template to 
check for DNA contamination revealed no specific amplification. PCR products were 
analyzed by electrophoresis on 2.5% agarose gels and visualized by ethidium bromide 
staining and the size of amplified products was compared with molecular weight 
markers run in parallel. Densitometric analysis was performed using the BIO1D 
software (Vilber Lourmat). 
 
Mononuclear cells 
Mononuclear cells were isolated from heparinized blood samples of four normal adult 
donors by Ficoll-Hypaque density gradient centrifugation and adjusted at 2x106 cells/ml 
in RPMI 1640 (with 10% FBS and 100 mg/ml Gentamycin). The mono-nuclear cells 
were cultured in a 12-well microtiter plate (2 million cells per well) and were stimulated 
with 10 µg/ml of LPS (Sigma, Madrid, Spain), 1 µg/m1 of TPA and various 
concentrations of Buflomedil or saline. After 24 h culture supernatants were harvested 
for IL-1β measurement and after 48 h for TNF-α, IL-6 and IL-8 measurements. The 
quantifications of there cytokines were estimated in duplicate by ELISA (R&D 
Systems, Minneapolis, MN) and the results expressed in pg/million cells. 
 
 
RESULTS 
 
In vitro effects of PTX on cytokine production by TPA-induced keratinocytes 
Turnor necrosis factor-α. As shown in Fig. 1, TPA induced TNF-α production by 
keratinocytes. Following PTX (100 µg/m1) stimulus, no effects on TNF-α synthesis 
were observed (Fig. 1). At a dose of 1000 µg/ml, protein synthesis was slightly 
increased. The addition of PTX to 1 pig/m1 TPA cultures slightly decreased TNF-α 
synthesis (Fig 1). After 24 h, however, the addition of PTX produced a slight increase in 
TNF-α in culture supernatants (media from 210 to 223 pg/ml) (data not shown). 
Concerning RNA expression, there was no observable change measured after either 4 
(Fig. 2a) or 8 h, nor was there any tendency of reduction in gene expression between 
specimens stimulated with 1 pg/m1 of TPA plus PTX at different concentrations and 
those stimulated only with TPA. When PTX (100 µg/m1) was added 2 h prior to 
stimulation with TPA, no change was observed. 
Interleukin-lα. Neither PTX alone in comparison with the control, nor the combination 
of TPA and PTX at the doses studied in comparison with TPA 1 µg/m1, affected the 
protein translation of IL-lα in culture supernatants, measured after 8 (Fig. 1) or 24 h 
(data not shown). Regarding RNA synthesis, PTX (1000 pg/m1) did not influence IL-lα 
expression. TPA (1 µg/ml) plus PTX (100-1000 pg/m1) produced no variation in the IL-
la RNA concentration measured after 4 h, but after 8 h this expression fell by a half (Fig 
2b). 
Interleukin-lβ. Neither PTX alone in comparison with control, nor the combination of 
TPA and PTX at the doses studied in comparison to TPA 1 µg/ml affected the protein 
translation of IL-lα in culture supernatants, either after 8 (Fig. 1) or 24 h (data not 
shown). As for RNA, PTX (1000 µg/ml) by itself neither stimulated nor inhibited IL-1β 
synthesis in comparison with control. Unlike IL-lα, the combination of TPA (1 µg/ml) 
plus PTX (100 or 1000 µg/ml) after 4 h induced a non dosedependent reduction by half 
— with respect to TPA (1 µg/ml) — in the expression of the IL-1β gene (Fig. 2c). No 
observable changes were found after 8 h. 
Interleukin 8. TPA induced IL-8 production by keratinocytes. The addition of PTX to 
TPA 1 µg/ ml or control cultures, did not affect IL-8 protein levels after 8 h (Fig. 1) or 
24 h (data not shown). 
 
In vitro effects of BC on cytokine production by TPA-induced keratinocytes 
Tumor necrosis factor-α. As shown in Fig. 3, TPA induced TNF-α production by 
keratinocytes. Following BC (100 and 1000 pg/m1) stimulus no effects on TNF-α 
synthesis were observed. The combination of TPA and BC at the studied doses, showed 
a significant dose-dependent inhibition of protein synthesis after 8 h, with staggered 
inhibition of the production of this cytokine, proportional to the doses of BC from 100 
µg/ml (Fig. 3) to 2000 ing/m1 (data not shown). Regarding TNF-α RNA analysis, 
expression remained constant with TPA plus BC (100 µg/m1) with respect to TPA 1 
mg/m1; however, a dose of 1000 µg/ml BC decreased the expression of this cytokine 
measured after 8 h (Fig. 4a). When BC (10, 50 or 100 µg/ml) was added 2 h prior to 
stimulation with TPA, keratinocytes-derived TNF-α expression remained constant. 
Interleukin-la. As with PTX, BC added to control or TPA induced cultures had no 
influence on IL-lα protein measured after 8 (Fig. 3) or 24 h (data not shown). Regarding 
RNA, BC (1000 pg/ ml) did not stimulate nor inhibit IL- la expression. After TPA (1 
µg/ml) stimulation, low doses of BC (100 µg/m1) produced no effect on IL-la RNA. 
Higher doses (1000 pg/m1) produced a 50 or 75% reduction of IL-lα RNA expression 
measured after 4 (Fig. 4b) and 8 h. 
Interleukin-1β. BC added to control or TPA 1 µg/m1 cultures, had no influence on IL-
1β protein translation measured after 8 (Fig. 3) or 24 h (data not shown). Concerning 
RNA, the addition of BC (1000 µg/ml) increased by 2 to 2.5 times the expression of the 
IL-1β gene; however, after stimulation with 1 µg/ml of TPA, BC at doses of 100-1000 
µg/m1 reduced by as much as 50% and 15% this cytokine's expression measured after 4 
and 8 h, this inhibition being most evident after 4 h (Fig. 4c). 
Interleukin 8. BC (100 to 1000 µg/ml) slightly increased the synthesis of IL-8. Addition 
of BC to TPA keratinocyte cultures induced a dose-dependent inhibition of protein 
synthesis after 8 h. After both 8 and 24 h, addition of 1000 µg/m1 of BC made IL-8 
levels fall almost to half with respect to TPA 1 µg/m1 (Fig. 3). Unstimulated 
keratinocytes did not express IL-8 RNA. Treatment with 100 ng/ ml TPA resulted in a 
marked increase of IL-8 RNA after 8 h (Fig. 5). Preincubation with BC for 2 h prior to 
stimulation with TPA resulted in a dosedependent reduction of keratinocytes-derived 
IL-8 expression (Fig. 5). 
Transforming Growth factor-β1. We did not perform assays for TGF-β1 in culture 
supernatants. BC or PTX (100 and 1000 µn/m1) did not inhibit nor stimulate RNA 
expression of TGF-β1 induced by TPA 1 mg/ml measured after 4 and 8 h (data not 
shown). 
 
In vitro effects of BC on cytokine production by TPA or LPS-induced 
mononuclear peripheral blood cells 
As shown in Fig. 6, TPA induced TNF-α, IL-1β, IL-6 and IL-8 production by 
mononuclear peripheral blood cells. BC at doses of 50, 100 and 1000 pg/m1 did not 
inhibit nor stimulate TNF-α, IL-1β, IL-6 and IL-8 protein synthesis, measured after 24 
h, in TPA 1 pg/m1 (Fig. 6) or LPS 10 µg/ml (data not shown) induced cultures. In 
contrast similar experiments with dexamethasone decreased cytokine levels in culture 
supernatants (data not shown). 
 
 
DISCUSSION 
 
PTX is a methylxanthine derivative that functions as a phosphodiesterase inhibitor (24). 
PTX is well known for its hemorrheologic and anti-inflammatory properties (10, 13, 25-
27). Recent studies in animals have shown the effects of PTX in inhibiting the afferent 
phase of contact eczema. This effect has been attributed to inhibition of TNF-α 
synthesis (28). The same research team has demonstrated in vitro how PTX suppresses 
UVB-induced TNF-α, IL-1 and IL-6 release by keratinocytes, while not after 
stimulation with a phorbol derivate (29). In our trials PTX was found not to have a clear 
and significant inhibitory action on the synthesis of TNF-α (Fig. 1). Regarding RNA, 
there was no significant difference between the levels found in the specimens stimulated 
with TPA plus PTX and the control samples stimulated with TPA alone (Fig. 2a). These 
data show that PTX does not suppress TPA-induced TNF-α release from keratinocytes; 
whereas in other immune cells, PTX reduced LPS or anti-CD3-induced TNF-α 
expression, probably via the generation of intracellular cAMP (13, 25, 30). 
Theoretically there are two possible explanations for this last fact. On one hand, we may 
attribute this lack of immunomodulatory capacity to the degree of differentiation 
reached by these keratinocytes, or it may be specific to the studied cell line. On the 
other hand, a more plausible hypothesis can be proponed, in which TPA increases TNF-
α via PKC, with PTX not being able to modify this pathway. PTX does not suppress 
TPA-induced IL-8 release by keratinocytes (Fig. 1), data that agrees with that obtained 
in vivo by Martich et al. (31). 
However, in our cultures BC caused a dose-dependent reduction in TNF-α and IL-8 
synthesis (Fig. 3). BC (1000 µg/m1) reduced TPA-induced TNF-α expression (Fig. 4a). 
BC inhibition of TPAinduced IL-8 upregulation could occur at transcriptional level 
(Fig. 5). It may happen, also, that the inhibiting effect of BC on TNF-α synthesis is 
exerted during transcription. Nevertheless, in cultures of different cell lines such as 
mononuclear blood cells, and lower doses such as 100 µg/ml, different results were 
obtained. 
IL-lα and IL-1β RNA expression were increased after TPA stimulation. We did not 
perforen nuclear run-on assays, and so were unable to distinguish between an increase 
in transcription and an in-crease in the stability of the RNA of the two cytokines. PTX 
reduced TPA-induced IL-1α and IL-1β RNA (Fig. 2b, 2c). These findings were more 
obvious in the case of BC (Fig. 4b, 4c). No changes in IL-lα or IL-1β levels, after TPA 
stimulation or different combinations with PTX and BC, were detected, being similar to 
those found in the control in almost all assays (Figs 1 and 3). Although we did not 
perform cell lysis in order to measure the intracellular protein production, probably 
these results suggest a secretion deficiency rather than an abnormality in the synthesis 
of these two cytokines. Although TPA is a significant inducer of IL-1, also it has been 
demonstrated that TPA can induce surface IL-1 receptor (R) in keratinocyte cultures. 
Some studies in human keratinocytes demonstrated that at 24 h after TPA treatment 
there was only a slight increase in detectable IL- I released to the supernatants, and there 
was an in-crease of 9- to 20-fold in surface IL-1R levels per cell in postconfluent 
cultures (32). Low levels of supernatant IL-1 activity in our keratinocyte cultures after 
TPA treatment may be partly due to interaction between IL-1 and IL-1R. In this way it 
is difficult to explain the theoretical downregulator effect of PTX or BC about these 
cytokines. The mechanism by which BC acts is not totally understood. It acts as an a-
adrenergic antagonist (mainly a-2), stimulating adenyl cyclase, therefore increasing 
intracellular cAMP (33). BC at high doses seems to have a non-specific calcium and 
sodium antagonist channel action. 
There are different opinions in the literature with regard to the modulation of IL-1 by 
substances which increase cAMP. In this way, some authors (34, 35) show that PTX or 
other xanthines suppress LPS-induced IL-1 release by monocytes. On the other hand, 
both myeloid leukemia cells and human monocytes show an increase in IL-1β 
production when stimulated simultaneously by phorbol derivates and cAMP analogs 
(dibutyryl cAMP) or substances, such as PGE2, which raises the endogenous levels of 
cAMP (35, 36). Other authors (37) found that an inhibition of this cytokine was 
produced by substances which increase the cGMP, but not by those which raise the 
cAMP. In any case, these studies were not carried out on keratinocytes, and the results 
may therefore vary according to the cell line studied. Lastly, PTX and BC did not 
induce any effect on TPA-induced TGF-β1 RNA expression. In the literature we have 
been unable to find any reference to the action of PTX on this cytokine, either in 
keratinocytes or in other cell lines. 
From the aboye data, we can conclude that BC in vitro, under our experimental 
conditions can inhibit, in a dose-dependent way, TPA-induced cytokines by 
keratinocytes, specifically TNF-α and IL-8, and probably IL-1β and IL-la as well. 
Modulation of BC on TPA-induced IL-1α and expression is similar to that obtained 
with PTX and therefore could be related to the rise in cAMP produced by both drugs by 
different means. Unlike PTX, BC alone raises the IL-10 RNA expression, but does not 
affect the transcription of IL-lα. This action may also be attributable to the intracellular 
rise in cAMP, although this mechanism would not entirely account for the inhibiting 
action of BC on TPA-induced TNF-α and IL-8 synthesis, as such an inhibition is not 
produced in the case of PTX. 
Further studies should be performed on keratinocytes and other immune cells in order to 
confirm these findings and determine the mechanism by which they act. It may be that 
BC, by increasing the cAMP and exerting a calcium antagonist effect, or by some 
unknown mechanism, can inhibit PKC, act on some stage of the complex cascade of 
protein synthesis, or interfere with cell transcription. It may be that BC's action is 
specifically exerted on keratinocytes, as we found no similar results concerning the 
synthesis of TNF-α and IL-8 in peripheral blood mononuclear cells (Fig. 6). These 
findings may help us find new topical or systemic applications for a drug that is widely 
used in everyday clinical practice. 
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Figure 1. Determination of TNF-α, IL-1α, IL-1β and IL-8 concentration in cultured 
supernatants. The KC were cultured in basal K-SFM without BPE and EGF for 72 h 
before induetion. Human KC were cultured for 8 h with PTX 1000 (1000 µg/ml), TPA 
(1 µg/ml), TPA + PTX 100 (1 µg/ml +100 µg/ml), TPA + PTX 1000 (1 µg + 1000 
ng/ml) and under basal conditions (control). Supernatants were tested for cytokines in 
triplicate using ELISA kits. Data teptesent the mean±SD of three experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Regulation of cytokine RNA extracted from KC following TPA and PTX 
exposure. Lane 1: control: lane 2: PTX 1000 µg/ml; lane 3: TPA 1 µg/ml; lane 4: TPA 
(1 µg/ml) + PTX (100 µg/ml): lane 5: TPA (1 ng/ml) + PTX (1000 µg/ml). Northern 
blot analysis was performed on KC treated with ttie indicated concentrations of TPA 
and PTX, and total cellular RNA was analyzed (5 µg per lane) for cytokine RNA 
expression. β-actin probing was performed to ensure uniformity of loading and transfer 
of RNA. 
A) TNF-α RNA expression 4 h after exposure. Densitometry results are plotted in 
artiitrary units of TNF-α/β-actin densitometry values, with conlrol (lane 1) TNF-α/β-
actin=l. B) IL-lα RNA expression 8 h after exposure. Densitometry results were 
calculated and plotted as in A). C) IL-1β RNA expression 4 h after exposure. 
Densitometry results were calculated and plotted as in A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Determination of TNF-α, IL-lα. 1L-1β and IL-8 concentration in cultured 
supernatants. The KC were cultuted in basal K-SFM without BPE and EGF for 72 h 
before induction. Human KC were cultured for 8 h with BC 1000 (1000 µg/ml), TPA (I 
µg/ml), TPA + BC 100 (1 µg/ml + lOO µg/ml), TPA + BC 1000 (I µg + lOOO µg/ml) 
and under basal conditions (control). Supernatants were tested for cytokines in triplicate 
using ELl- SA kits. Data represent the mean±SD of three experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Regulation of cytokine RNA extracted from KC following TPA and BC 
exposure. Lane 1: control; lane 2: BC 1000 µg/Ml; lane 3: TPA 1 µg/ml; lane 4: TPA (1 
µg/ml)+BC (100 µg/ml); lane 5: TPA (1 µg/ml) + BC (1000 µg/ml). Northern blot 
analysis was performed on KC treated with the indicated concentrations of TPA and 
BC. and total cellular RNA was analyzed (5 µg per lane) for cytokine RNA expression. 
Β actin probing was performed to ensure uniformity of loading and transfer of RNA. 
Densitometry results were calculated and plotted as in Fig. 2. A) TNF-α RNA 
expression 8 h after exposure. B) IL-1α RNA expression 4 h after exposure. C) IL-1β 
RNA expression 4 h after exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Regulation of IL-8 RNA extracted from KC following TPA and BC exposure 
(after 8 h). Lane 1: control: lane 2: BC 100 µg/ml; lane 3: TPA 100 ng/ml; lane 4; TPA 
(100 ng/ml) + BC (100 µg/ml); lane 5: TPA (100 ng/ml)+BC (50 µg/ml); lane 6: TPA 
(100 ng/ml) + BC (10 µg/ml). RT-PCR analysis was performed on KC treated with the 
indicated concentrations of TPA and BC, and total cellular RNA was analyzed for IL-8 
RNA expression. β-actin probing was performed lo ensure uniformity of loading and 
transfer of RNA. Densilometry results were calculated and plotted as in Fig. 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Determination of TNF-α, IL-1β, IL-6 and lL-8 concentration in cultured 
supernatants. Mononuclear cells were cultured for 24 h with TPA (1 µg/ml), TPA + BC 
(50) (1 µg/ml + 50 µg/ml), TPA + BC (100) (1 µg + lOO µg/ml). TPA + BC (1000) (1 
µg/ml+1000 µg/ml) and under basal conditions (control). Supernatants were tested for 
cytokines in triplicale using ELISA kits. Data represent the mean±SD of four 
experiments. 
